Israeli clinical-stage immunotherapy company Enlivex Therapeutics announced the purchase of Bitcoin as part of its corporate asset reserves

ChainCatcher news, Israeli clinical-stage immunotherapy company Enlivex Therapeutics announced that its board has approved the allocation of up to $1 million for the purchase of Bitcoin as part of its cash management strategy.

The company is listed on the NASDAQ in the United States (ticker: ENLV). CEO Oren Hershkovitz stated that with the growing demand and acceptance of Bitcoin, along with the recent approval of Bitcoin ETFs and support from institutional investors, the company believes that Bitcoin can serve as a strong asset reserve, providing value storage and anti-inflation capabilities.